<h4>Background</h4>Ozanimod is a once-daily oral selective sphingosine 1-phosphate receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC) or relapsing multiple sclerosis (RMS). The gene discussed is S1PR1; the disease is ulcerative colitis.